• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Normiflo

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Normiflo

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Normiflo (andeparin sodium,)a low molecular weight heparin cleared for use in prevention of deep venous thrombosis (DVT), differs from others in its class by allowing the orthopedic surgeon to determine dosing based on a patient’s weight. The new dosing method eliminates the need for daily dosage adjustments and routine coagulation laboratory monitoring. Venous thromboembolic disease includes DVT, the formation of blood clots following surgery and its complications such as pulmonary embolism, which can be sudden and fatal.

    Clinical Results

    In one study, dosing regimens of Normiflo were compared to warfarin for preventing DVT in patients electing knee replacement surgery, a procedure that puts patients at high risk of developing the condition. Normiflo was found to be more effective than warfarin in preventing venous thromboembolism. Investigators concluded that ardeparin sodium was significantly more effective than warfarin and had a comparable safety profile. In another study, results showed that dosing based on body weight produced constant plasma antiXa levels. No routine coagulation monitoring is required during thromboprophylaxes with Normiflo. However, monitoring of complete blood counts, including platelet counts, urinalysis, and occult blood in stools, is recommended.

    Side Effects

    Normiflo should not be used in patients with active major bleeding, hypersensitivity to the drug, or thombocytopenia associate with a positive in vitro test for antiplatelet antibodies in the presence of Normiflo. Patients with a known hypersensitivity to ardeparin sodium or to pork products should not be treated with Normiflo. Bleeding can occur at virtually any site. If problematic bleeding occurs, Normiflo should be discontinued. Patients should be observed closely for bleeding if Normiflo is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.

    Additional Information

    Venous thromboembolic disease is considered to be responsible for more than 400,000 hospitalizations and up to 200,000 deaths in the U.S. alone. In the absence of prophylaxis with any agent or device, DVT is estimated to occur in 40% or 70% of patients following major orthopedic procedures with death resulting in 1% of knee replacement patients.

    Approval Date: 1997-05-01
    Company Name: Wyeth
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing